To develop an effective treatment or vaccine for Covid-19, scientists must understand how the immune system is impacted during the disease.
As the world is eagerly awaiting news of an effective and safe vaccine against Covid-19, several companies are moving ahead testing therapeutic antibodies against the disease.
GentiBio closed on a $20 million seed funding led by OrbiMed, Novartis Venture Fund and RA Capital Management. The company also announced exclusive licensing partnerships with Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason (BRK), and MIGAL Galilee Research Institute (MIGAL).
Developing an ‘Inverse Vaccine’ for Type 1 Diabetes Published: July 14, 2020 By Chelsea Weidman Burke BioSpace What do you get when you mix certain immune cells with vitamin D and a disease-provoking molecule? An innovative new vaccine for type 1 diabetes. “We are trying to educate the immune system to teach it what […]
Kiadis Pharma licensed a previously undisclosed K-NK0004 program to Sanofi covering Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutics for combination with anti-CD38 monoclonal antibodies.
A new study published in the journal Nano Letters showed that cellular nanosponges may be able to inhibit SARS-CoV-2 infectivity within the body, ultimately neutralizing the virus.
Vancouver, Washington-based CytoDyn filed a second clinical trial protocol with the U.S. Food and Drug Administration to treat severely sick COVID-19 patients.
Astellas Pharma Inc. bought U.S.-based Xyphos Biosciences Inc. to expand the Japanese drugmaker’s immuno-oncology business, a deal worth up to $665 million.
Bristol-Myers Squibb announced positive results for the CAR-T therapy lisocabtagene maraleucel (liso-cel) in three studies at the American Society of Hematology Annual Meeting.
Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?